SOPHiA GENETICS (SOPH) Scheduled to Post Earnings on Tuesday

SOPHiA GENETICS (NASDAQ:SOPH) is scheduled to announce its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, March 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.12). SOPHiA GENETICS had a negative net margin of 126.63% and a negative return on equity of 47.40%. The firm had revenue of $17.05 million for the quarter, compared to analyst estimates of $16.78 million. During the same quarter in the prior year, the firm posted ($0.22) EPS. On average, analysts expect SOPHiA GENETICS to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SOPHiA GENETICS Price Performance

Shares of SOPH traded up $0.08 during trading hours on Tuesday, reaching $5.14. The stock had a trading volume of 16,972 shares, compared to its average volume of 58,561. The firm has a 50-day moving average of $4.91 and a 200 day moving average of $4.49. SOPHiA GENETICS has a 52 week low of $2.13 and a 52 week high of $7.37.

Analyst Upgrades and Downgrades

SOPH has been the topic of a number of research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a research note on Wednesday, March 6th. BTIG Research upped their price objective on SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.